Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash & Equivalents (2016 - 2025)

Neurocrine Biosciences' Cash & Equivalents history spans 16 years, with the latest figure at $713.0 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 206.01% year-over-year to $713.0 million; the TTM value through Dec 2025 reached $713.0 million, up 206.01%, while the annual FY2025 figure was $713.0 million, 206.01% up from the prior year.
  • Cash & Equivalents reached $713.0 million in Q4 2025 per NBIX's latest filing, up from $340.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $713.0 million in Q4 2025 to a low of $103.8 million in Q1 2023.
  • Average Cash & Equivalents over 5 years is $286.9 million, with a median of $270.4 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: tumbled 61.58% in 2023, then surged 281.79% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $344.0 million in 2021, then dropped by 21.31% to $270.7 million in 2022, then decreased by 4.29% to $259.1 million in 2023, then dropped by 10.07% to $233.0 million in 2024, then surged by 206.01% to $713.0 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Cash & Equivalents are $713.0 million (Q4 2025), $340.2 million (Q3 2025), and $264.0 million (Q2 2025).